Free Trial

Autolus Therapeutics (AUTL) Stock Forecast & Price Target

Autolus Therapeutics logo
$3.20 -0.06 (-1.84%)
(As of 12/3/2024 ET)

Autolus Therapeutics - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
0
Buy
5

Based on 5 Wall Street analysts who have issued ratings for Autolus Therapeutics in the last 12 months, the stock has a consensus rating of "Buy." Out of the 5 analysts, 5 have given a buy rating for AUTL.

Consensus Price Target

$10.15
217.19% Upside
According to the 5 analysts' twelve-month price targets for Autolus Therapeutics, the average price target is $10.15. The highest price target for AUTL is $13.00, while the lowest price target for AUTL is $7.60. The average price target represents a forecasted upside of 217.19% from the current price of $3.20.
Get the Latest News and Ratings for AUTL and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Autolus Therapeutics and its competitors.

Sign Up

AUTL Analyst Ratings Over Time

TypeCurrent Forecast
12/5/23 to 12/4/24
1 Month Ago
11/5/23 to 11/4/24
3 Months Ago
9/6/23 to 9/5/24
1 Year Ago
12/5/22 to 12/5/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
5 Buy rating(s)
4 Buy rating(s)
4 Buy rating(s)
7 Buy rating(s)
Hold
0 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$10.15$8.70$8.70$8.17
Forecasted Upside217.19% Upside160.48% Upside95.95% Upside103.66% Upside
Consensus Rating
Buy
Moderate Buy
Moderate Buy
Buy

AUTL Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

AUTL Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Autolus Therapeutics Stock vs. The Competition

TypeAutolus TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.81
2.50
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside217.19% Upside26,784.61% Upside7.38% Upside
News Sentiment Rating
Positive News

See Recent AUTL News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/18/2024The Goldman Sachs Group
2 of 5 stars
R. Sharma
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$7.00 ➝ $7.60+146.75%
11/15/2024Redburn Atlantic
5 of 5 stars
S. Baker
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$13.00+331.89%
11/11/2024Needham & Company LLC
2 of 5 stars
 Reiterated RatingBuy ➝ Buy$9.00 ➝ $9.00+141.29%
6/3/2024William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform
4/9/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$10.00 ➝ $11.00+102.58%
11/9/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$10.00+170.27%
Tim Sykes’ Urgent Trade Alert: “Make this move now” (Ad)

WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…

Click here to see a unique election-year trade
5/5/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$8.00 ➝ $6.00+212.50%
3/17/2023Bryan, Garnier & Co
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$5.00+133.64%
3/8/2023Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$18.00 ➝ $12.00+525.00%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 04:25 AM ET.


AUTL Forecast - Frequently Asked Questions

According to the research reports of 5 Wall Street equities research analysts, the average twelve-month stock price forecast for Autolus Therapeutics is $10.15, with a high forecast of $13.00 and a low forecast of $7.60.

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Autolus Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AUTL shares.

According to analysts, Autolus Therapeutics's stock has a predicted upside of 217.19% based on their 12-month stock forecasts.

Over the previous 90 days, Autolus Therapeutics's stock had 2 upgrades by analysts.

Autolus Therapeutics has been rated by research analysts at Needham & Company LLC, Redburn Atlantic, and The Goldman Sachs Group in the past 90 days.

Analysts like Autolus Therapeutics more than other "medical" companies. The consensus rating for Autolus Therapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how AUTL compares to other companies.


This page (NASDAQ:AUTL) was last updated on 12/4/2024 by MarketBeat.com Staff
From Our Partners